A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 24,600 shares of KYMR stock, worth $1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,600
Previous 22,600 8.85%
Holding current value
$1 Million
Previous $674,000 72.7%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$30.16 - $52.4 $2.78 Million - $4.84 Million
-92,325 Reduced 60.09%
61,332 $2.9 Million
Q2 2024

Aug 14, 2024

SELL
$29.85 - $39.42 $3.22 Million - $4.25 Million
-107,724 Reduced 41.21%
153,657 $4.59 Million
Q1 2024

May 15, 2024

SELL
$22.9 - $43.57 $2.52 Million - $4.8 Million
-110,062 Reduced 29.63%
261,381 $10.5 Million
Q4 2023

Feb 14, 2024

BUY
$10.97 - $26.84 $1.67 Million - $4.09 Million
152,460 Added 69.62%
371,443 $9.46 Million
Q3 2023

Nov 14, 2023

SELL
$13.9 - $23.88 $842,326 - $1.45 Million
-60,599 Reduced 21.67%
218,983 $3.04 Million
Q2 2023

Aug 14, 2023

BUY
$22.4 - $34.92 $6.26 Million - $9.76 Million
279,364 Added 128148.62%
279,582 $6.43 Million
Q1 2023

May 15, 2023

SELL
$24.84 - $38.75 $690,328 - $1.08 Million
-27,791 Reduced 99.22%
218 $6,000
Q4 2022

Feb 14, 2023

SELL
$19.57 - $30.92 $462,047 - $730,021
-23,610 Reduced 45.74%
28,009 $699,000
Q3 2022

Nov 14, 2022

BUY
$20.91 - $34.27 $1.08 Million - $1.77 Million
51,619 New
51,619 $1.12 Million

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.22B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.